Recombinant anti-CD3 monoclonal antibody (Shanghai Zhangjiang Biotechnology)
重组抗CD3人源化单抗（上海张江生物）
Report date: 2022/07/15 15:58:57
Base Information
Drug NameRecombinant anti-CD3 monoclonal antibody (Shanghai Zhangjiang Biotechnology)
Drug Alias Name
Classification
Mechanisms of Action
Targets
Therapy Area/Indications
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/Territory
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaPending
Originator CompaniesShanghai Zhangjiang Biotechnology Co Ltd
China Registration ClassClass 1 therapeutic biologic in China
Develop Information
Active CompaniesN/A
Inactive CompaniesShanghai Zhangjiang Biotechnology Co Ltd
Active IndicationsN/A
Inactive Indications
Other Information
ATC CodeN/A
Related LinksN/A